FDA Clears Way for Phase 2 Trial of AV-101 for Levodopa-Induced Dyskinesia

FDA Clears Way for Phase 2 Trial of AV-101 for Levodopa-Induced Dyskinesia
VistaGen Therapeutics will begin a Phase 2 clinical trial to evaluate its lead candidate AV-101 as a potential treatment to reduce dyskinesia (abnormal involuntary movements) induced by levodopa in patients with Parkinson’s disease, after the U.S. Food and Drug Administration (FDA) cleared the company’s investigational new drug (IND) application. Parkinson’s is characterized by the loss of neurons that produce the ... read more
Source: Parkinson’s News TodayPublished on 2020-02-04By Patricia Inacio, PhD